Cost-effectiveness of lenalidomide plus rituximab versus rituximab monotherapy in patients with previously treated follicular lymphoma: a societal view

References

• Freedman A. Follicular lymphoma: 2018 update on diagnosis and management. Am J Hematol. 2018;93(2):296–305.
   PubMed Web of Science ®Google Scholar
• Dinnessen M, Brink M, Korf-van Vliet C, et al. Het folliculair lympfoom in Nederland, 2014-2016. Landelijk rapport van het hematooncologieregister van de Nederlandse Kankerregistratie. [Internet]. 2019 [cited 2020 Apr 21]. Available from: https://www.iknl.nl/getmedia/6fbcaf47-2677-4b4e-933d-68d5be07773b/Hematologische_kankersoorten_landelijk_rapport_iknl_FL_2014_2016.pdf.
   Google Scholar
• Kharchenko EV, Sweetenham JW. Advances in relapsed/refractory follicular lymphoma therapeutics. Adv Cell Gene Ther. 2020;3(1):e74.
   Google Scholar
• Anonymous. Zevalin [Internet]. Eur. Med. Agency. 2018 [cited 2020 Mar 30]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/zevalin.
   Google Scholar
• Anonymous. Zydelig [Internet]. Eur. Med. Agency. 2018 [cited 2020 Mar 30]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/zydelig.
   Google Scholar
• Anonymous. Gazyvaro [Internet]. Eur. Med. Agency. 2018 [cited 2020 Mar 30]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/gazyvaro.
   Google Scholar
• Anonymous. MabThera [Internet]. Eur. Med. Agency. 2018 [cited 2020 Mar 29]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/mabthera.
   Google Scholar
• Anonymous. IntronA [Internet]. Eur. Med. Agency. 2018 [cited 2020 Mar 29]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/introna.
   Google Scholar
• European Medicines Agency. EMA/225905/2019. Revlimid (lenalidomide) [Internet]. [cited 2019 Dec 2]. Available from: https://www.ema.europa.eu/en/documents/overview/revlimid-epar-medicine-overview_en.pdf.
   Google Scholar
• Leonard JP, Trneny M, Izutsu K, et al. AUGMENT: a Phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma. J Clin Oncol Off J Am Soc Clin Oncol. 2019;37(14):1188–1199.
   Google Scholar
• Fayers P, Bottomley A. on behalf of the EORTC quality of life group and of the quality of life unit. Quality of life research within the EORTC—the EORTC QLQ-C30. Eur J Cancer. 2002;38:125–133.
   PubMed Web of Science ®Google Scholar
• Rabin R, De CF. EQ-5D: a measure of health status from the EuroQol Group. Ann Med. 2001;33(5):337–343.
   PubMed Web of Science ®Google Scholar
• Leonard JP, Trněny M, Izutsu K, et al. Health-Related Quality of Life (HRQoL) in Relapsed/Refractory (r/r) Indolent NHL in the Phase 3 AUGMENT Trial of Rituximab (R) plus Lenalidomide (R 2) versus R plus Placebo. Hematol Oncol. 2019;37:232–234.
   Google Scholar
• Dhanasiri S. Response to: olry de Labry Lima A et al., Cost-effectiveness of lenalidomide maintenance in patients with multiple myeloma who have undergone autologous transplant hematopoietic progenitor cells. Bone Marrow Transplant. 2019;1–2.
   Web of Science ®Google Scholar
• Briggs A, Sculpher M, Claxton K. Decision modelling for health economic evaluation. Oxford: Oxford University Press; 2006.
   Google Scholar
• Drummond MF, Sculpher M, Claxton K, et al. Methods for the economic evaluation of health care programmes [Internet]. Oxford: Oxford University Press; 2015 [cited 2020 Mar 26]. Available from: https://doi.org/10.1136/jech.41.4.355-a.
   Google Scholar
• Brouwer WBF, van Exel NJA, Baltussen RMPM, et al. A dollar is a dollar is a dollar—or is it? Value Health. 2006;9(5):341–347.
   PubMed Web of Science ®Google Scholar
• Meltzer D. Accounting for future costs in medical cost-effectiveness analysis. J Health Econ. 1997;16(1):33–64.
   PubMed Web of Science ®Google Scholar
• Feenstra TL, Van Baal PHM, Gandjour A, et al. Future costs in economic evaluation: a comment on Lee. J Health Econ. 2008;27(6):1645–1649.
   PubMed Web of Science ®Google Scholar
• De Vries LM, Van Baal PHM, Brouwer WBF. Future costs in cost-effectiveness analyses: past, present, future. PharmacoEconomics. 2019;37(2):119–130.
   PubMed Web of Science ®Google Scholar
• PAID [version 3.0] [Internet]. iMTA. [cited 2020 Mar 26]. Available from: https://www.imta.nl/paid/.
   Google Scholar
• Van Baal PHM, Wong A, Slobbe LCJ, et al. Standardizing the inclusion of indirect medical costs in economic evaluations. PharmacoEconomics. 2011;29(3):175–187.
   PubMed Web of Science ®Google Scholar
• Kellerborg K, Perry-Duxbury M, De Vries L, et al. Practical guidance for including future costs in economic evaluations. Yet Publ.
   Google Scholar
• Woods B, Sideris E, Palmer S, et al. Partitioned survival analysis for decision modelling in health care: a critical review report. NICE Decis Support Unit. 2017;1–72.
   Google Scholar
• Hakkaart-van Roijen L, Van Der Linden N, Bouwamans C, et al. Kostenhandleiding: methodologie van kostenonderzoek en referentieprijzen voor economische evaluaties in de gezondheidszorg. Bijlage. 2016;1.
   Google Scholar
• Latimer NR. Survival analysis for economic evaluations alongside clinical trials - extrapolation with patient-level data: inconsistencies, limitations, and a practical guide. Med Decis Mak. 2013;33(6):743–754. 2013/01/24ed.
   PubMed Web of Science ®Google Scholar
• Z-Index - About [Internet]. [cited 2020 Mar 26]. Available from: https://www.z-index.nl/english.
   Google Scholar
• Franken MG, Kanters TA, Coenen JL, et al. Potential cost savings owing to the route of administration of oncology drugs: a microcosting study of intravenous and subcutaneous administration of trastuzumab and rituximab in the Netherlands. Anticancer Drugs. 2018;29(8):791–801.
   PubMed Web of Science ®Google Scholar
• Bouwmans C, Janssen J, Huijgens P, et al. Costs of haematological adverse events in chronic myeloid leukaemia patients: a retrospective cost analysis of the treatment of anaemia, neutropenia and thrombocytopenia in patients with chronic myeloid leukaemia. J Med Econ. 2009;12(2):164–169.
   PubMedGoogle Scholar
• Nafees B, Stafford M, Gavriel S, et al. Health state utilities for non small cell lung cancer. Health Qual Life Outcomes. 2008;6(1):84.
   PubMed Web of Science ®Google Scholar
• Swinburn P, Lloyd A, Nathan P, et al. Elicitation of health state utilities in metastatic renal cell carcinoma. Curr Med Res Opin. 2010;26(5):1091–1096.
   PubMed Web of Science ®Google Scholar
• Nederlandse Vereniging voor Hematologie. Richtlijn voor de diagnostiek, behandeling en follow-up van het folliculair lymfoom [Internet]. 2020 [cited 2020 Feb 19]. Available from: http://www.hovon.nl/upload/File/Richtlijnen_BehAdv/FL%20richtlijn_revisie2019.pdf.
   Google Scholar
• Statistics Netherlands. Open data [Internet]. Stat. Neth. [cited 2020 Mar 27]. Available from: https://www.cbs.nl/en-gb/our-services/open-data.
   Google Scholar
• The iMTA disease burden calculator [version 1.3 beta] [Internet]. [cited 2020 Mar 26]. Available from: www.imta.nl/idbc.
   Google Scholar
• Zorginstituut Nederland. Richtlijn voor het uitvoeren van economische evaluaties in de gezondheidszorg [Internet]. 2016 [cited 2020 Mar 11]. Available from: https://www.zorginstituutnederland.nl/publicaties/publicatie/2016/02/29/richtlijn-voor-het-uitvoeren-van-economische-evaluaties-in-de-gezondheidszorg.
   Google Scholar
• Doorduijn JK, Buijt I, Van Der Holt B, et al. Economic evaluation of prophylactic granulocyte colony stimulating factor during chemotherapy in elderly patients with aggressive non-Hodgkin’s lymphoma. Haematologica. 2004;89:1109–1117.
   PubMed Web of Science ®Google Scholar
• Arboe B, Olsen MH, Goerloev JS, et al. Return to work for patients with diffuse large B-cell lymphoma and transformed indolent lymphoma undergoing autologous stem cell transplantation. Clin Epidemiol. 2017;9:321–329.
   PubMed Web of Science ®Google Scholar
• Single Technology Appraisal. Lenalidomide for treated follicular lymphoma and marginal zone lymphoma [ID1374]. Committee Papers [Internet]. National Institute for Health and Care Excellence; 2020 [cited 2020 Mar 30]. Available from: https://www.nice.org.uk/guidance/gid-ta10323/documents/committee-papers.
   Google Scholar
• Final appraisal document. Lenalidomide with rituximab for previously treated follicular lymphoma. [Internet]. National Institute for Health and Care Excellence; 2020 [cited 2020 Mar 30]. Available from: https://www.nice.org.uk/guidance/gid-ta10323/documents/final-appraisal-determination-document.
   Google Scholar
• Zhang P-F, Xie D, Wen F, et al. Lenalidomide plus rituximab Vs rituximab alone in relapsed or refractory indolent lymphoma: a cost-effectiveness analysis. Cancer Med [Internet]. [cited 2020 Jun 17]; n/a. Available from: https://doi.org/10.1002/cam4.3121.
   Google Scholar
• Wild D, Walker M, Pettengell R, et al. PCN62 utility elicitation in patients with follicular lymphoma. Value Health. 2006;9(6):A294.
   Web of Science ®Google Scholar
• Monga N, Garside J, Gurung B, et al. Cost-Effectiveness analyses, costs and resource use, and health-related quality of life in patients with follicular or marginal zone lymphoma: systematic reviews. Pharmacoecon Open. 2020;4(4):575–591.
   PubMed Web of Science ®Google Scholar
• Morschhauser F, Fowler NH, Feugier P, et al. Rituximab plus Lenalidomide in advanced untreated follicular lymphoma. N Engl J Med. 2018;379(10):934–947.
   PubMed Web of Science ®Google Scholar
• van Rijn M. Regeling van de Minister voor Medische Zorg van 18 mei 2020, kenmerk 1687653-205139-Z, houdende wijziging van de Regeling zorgverzekering in verband met de opname van het geneesmiddel lenalidomide in het basispakket. Staatscourant; 2020.
   Google Scholar